Meneses-Lorente, Georgina
Fowler, Stephen
Guerini, Elena
Kowalski, Karey
Chow-Maneval, Edna
Yu, Li
Mercier, Francois
Ullah, Mohammed
Umehara, Kenichi
Brink, Andreas
Buchheit, Vincent
Zwanziger, Elke
Phipps, Alex
Djebli, Nassim
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd (formerly Ignyta Inc., a member of the Roche Group
F. Hoffmann-La Roche
Article History
Received: 15 April 2021
Accepted: 26 July 2021
First Online: 21 August 2021
Declarations
:
: All studies were approved by the relevant ethics committees, and were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.
: Registration number (Study 2): NCT03330990 (first posted online November 6, 2017). As studies 1 and 3 are phase 1 trials in healthy subjects, they are not required to be registered.
: In all 3 studies, subjects provided written informed consent.
: Informed consent was obtained from all individual participants included in the study.
: G.M-L. is an employee of Roche Products Ltd, E.G. and A.P. are employees and stockholders of F. Hoffmann-La Roche Ltd, N.D. is an employee of Ignyta (owned by F. Hoffmann-La Roche Ltd), E. C-M. and K.K. were employees of Ignyta (owned by F. Hoffmann-La Roche Ltd) during the time this work was conducted, F.M., V.B., A.B., S.F., E.Z. and K.U. are employees of Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland, M. U. was an employee of Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland during the time this work was conducted, L.Y. is a former employee of the Roche Innovation Center, Little Falls, NJ, USA.